Anti-Hypertensive Drugs - LATAM

LATAM

Revenue in the Anti-Hypertensive Drugs market is projected to reach US$0.86bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 0.00%, resulting in a market volume of US$0.86bn by 2028.
In global comparison, most revenue will be generated in the United States (US$12,290.00m in 2024).

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The objective of anti-hypertensive drugs is to prevent the risks of high blood pressure, such as strokes and myocardial infarction. This highlights the importance of this market for a large number of patients, and, as a consequence, it is one of the largest markets in terms of numbers of prescriptions. In terms of types of medication, calcium channel blockers are seen as the most important growth driver. Nevertheless, global revenue is expected to decrease slightly because of a high share of generics and the resulting price competition.

On a global level, only a small negative impact of the COVID-19 pandemic can be seen. As they did not consider hypertension an acute problem, patients avoided seeing doctors during the initial phase of the COVID-19 pandemic, leading to a decrease in prescriptions and revenue. This 2020 downturn was only moderate because the majority of patients continued their long-term treatment.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.